Bank of New York Mellon’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.02M | Buy |
297,722
+112,387
| +61% | +$425K | ﹤0.01% | 3348 |
|
|
2026
Q1 | $773K | Sell |
185,335
-3,270
| -2% | -$13.8K | ﹤0.01% | 3369 |
|
|
2025
Q4 | $519K | Sell |
188,605
-742
| -0.4% | -$2.12K | ﹤0.01% | 3593 |
|
|
2025
Q3 | $649K | Buy |
189,347
+9,738
| +5% | +$35.5K | ﹤0.01% | 3448 |
|
|
2025
Q2 | $618K | Buy |
179,609
+20,243
| +13% | +$53.4K | ﹤0.01% | 3394 |
|
|
2025
Q1 | $339K | Buy |
159,366
+15,897
| +11% | +$47.7K | ﹤0.01% | 3654 |
|
|
2024
Q4 | $458K | Buy |
143,469
+4,693
| +3% | +$38.3K | ﹤0.01% | 3568 |
|
|
2024
Q3 | $1.85M | Buy |
138,776
+1,508
| +1% | +$20.1K | ﹤0.01% | 2788 |
|
|
2024
Q2 | $1.37M | Buy |
137,268
+132,896
| +3,040% | +$1.92M | ﹤0.01% | 3009 |
|
|
2024
Q1 | $52K | Sell |
4,372
-11,052
| -72% | -$94.2K | ﹤0.01% | 4080 |
|
|
2023
Q4 | $62K | Hold |
15,424
| – | – | ﹤0.01% | 4141 |
|
|
2023
Q3 | $42.2K | Hold |
15,424
| – | – | ﹤0.01% | 4180 |
|
|
2023
Q2 | $103K | Hold |
15,424
| – | – | ﹤0.01% | 4083 |
|
|
2023
Q1 | $98.4K | Buy |
15,424
+7,701
| +100% | +$31.4K | ﹤0.01% | 4082 |
|
|
2022
Q4 | $19.1K | Hold |
7,723
| – | – | ﹤0.01% | 4363 |
|
|
2022
Q3 | $18K | Hold |
7,723
| – | – | ﹤0.01% | 4461 |
|
|
2022
Q2 | $24K | Hold |
7,723
| – | – | ﹤0.01% | 4475 |
|
|
2022
Q1 | $28K | Sell |
7,723
-2,200
| -22% | -$8.02K | ﹤0.01% | 4597 |
|
|
2021
Q4 | $39K | Hold |
9,923
| – | – | ﹤0.01% | 4532 |
|
|
2021
Q3 | $63K | Hold |
9,923
| – | – | ﹤0.01% | 4401 |
|
|
2021
Q2 | $80K | Buy |
9,923
+7,443
| +300% | +$65.2K | ﹤0.01% | 4253 |
|
|
2021
Q1 | $27K | Buy |
2,480
+280
| +13% | +$4.23K | ﹤0.01% | 4307 |
|
|
2020
Q4 | $10K | Buy |
+2,200
| New | +$9.72K | ﹤0.01% | 4205 |
|
|
2019
Q2 | – | Sell |
-6,537
| Closed | -$24K | – | 4218 |
|
|
2019
Q1 | $24K | Sell |
6,537
-205
| -3% | -$800 | ﹤0.01% | 4150 |
|
|
2018
Q4 | $20K | Hold |
6,742
| – | – | ﹤0.01% | 4156 |
|
|
2018
Q3 | $35K | Hold |
6,742
| – | – | ﹤0.01% | 4164 |
|
|
2018
Q2 | $30K | Sell |
6,742
-1,593
| -19% | -$7.37K | ﹤0.01% | 4145 |
|
|
2018
Q1 | $35K | Buy |
8,335
+1,299
| +18% | +$5.73K | ﹤0.01% | 4218 |
|
|
2017
Q4 | $28K | Buy |
7,036
+294
| +4% | +$1.37K | ﹤0.01% | 4268 |
|
|
2017
Q3 | $35K | Hold |
6,742
| – | – | ﹤0.01% | 4163 |
|
|
2017
Q2 | $42K | Sell |
6,742
-1,547
| -19% | -$8.76K | ﹤0.01% | 4155 |
|
|
2017
Q1 | $49K | Buy |
8,289
+1,547
| +23% | +$9.05K | ﹤0.01% | 4142 |
|
|
2016
Q4 | $39K | Sell |
6,742
-444
| -6% | -$2.72K | ﹤0.01% | 4159 |
|
|
2016
Q3 | $52K | Sell |
7,186
-1,379
| -16% | -$10.5K | ﹤0.01% | 4133 |
|
|
2016
Q2 | $75K | Sell |
8,565
-396
| -4% | -$3.79K | ﹤0.01% | 4110 |
|
|
2016
Q1 | $81K | Hold |
8,961
| – | – | ﹤0.01% | 4004 |
|
|
2015
Q4 | $84K | Hold |
8,961
| – | – | ﹤0.01% | 4095 |
|
|
2015
Q3 | $125K | Hold |
8,961
| – | – | ﹤0.01% | 4051 |
|
|
2015
Q2 | $132K | Buy |
8,961
+1,221
| +16% | +$19.8K | ﹤0.01% | 3987 |
|
|
2015
Q1 | $122K | Sell |
7,740
-63
| -0.8% | -$935 | ﹤0.01% | 4001 |
|
|
2014
Q4 | $114K | Buy |
7,803
+63
| +0.8% | +$998 | ﹤0.01% | 4011 |
|
|
2014
Q3 | $130K | Hold |
7,740
| – | – | ﹤0.01% | 3986 |
|
|
2014
Q2 | $242K | Buy |
7,740
+6,550
| +550% | +$164K | ﹤0.01% | 3792 |
|
|
2014
Q1 | $26K | Buy |
+1,190
| New | +$12.1K | ﹤0.01% | 4134 |
|
Other funds holding CATX
NWMG
HBT
WIM
N
GCP
Bank of New York Mellon's CATX Position: Q2 2026 in Review
Bank of New York Mellon increased its Perspective Therapeutics (CATX) stake by 61% in Q2 2026, buying an estimated $425K and bringing the position to 297,722 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #3348.
Bank of New York Mellon first reported a position in CATX in Q1 2014 and has held it in 44 quarters since. The position peaked at $1.85M in Q3 2024. 57 funds tracked by Wall St. Rank hold CATX as of Q2 2026.
- Bank of New York Mellon held 297,722 shares of Perspective Therapeutics worth $1.02M as of Q2 2026.
- Bank of New York Mellon bought 112,387 Perspective Therapeutics shares in Q2 2026, an estimated $425K.
- Perspective Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3348 holding.
- Bank of New York Mellon first reported a position in Perspective Therapeutics in Q1 2014 and has held it in 44 quarters since.
- Bank of New York Mellon's Perspective Therapeutics position peaked at $1.85M in Q3 2024.
- 57 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.